Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.44 |
| ▸ | PPARG | P37231 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482017 | 0.84 | EPHX2 (0.46) | EPHX2PPARGPOLBIDO1SCN8A | |
| SCHEMBL800327 | 0.84 | EPHX2 (0.46) | EPHX2PPARGPOLBIDO1SCN8A | |
| SCHEMBL25938010 | 0.80 | SLC6A2 (0.42) | EPHX2PPARGIDO1 | |
| SCHEMBL13865872 | 0.79 | HDAC4 (0.49) | EPHX2PPARGMRGPRX1 | |
| SCHEMBL30412531 | 0.77 | SIGMAR1 (0.51) | EPHX2PPARGPOLBMAPK1IDO1 | |
| SCHEMBL10379774 | 0.77 | SIGMAR1 (0.51) | EPHX2PPARGPOLBMAPK1IDO1 | |
| SCHEMBL12153073 | 0.75 | SCN8A (0.52) | EPHX2PPARGPOLBIDO1SCN8A | |
| SCHEMBL12153198 | 0.75 | SCN8A (0.49) | EPHX2PPARGIDO1SCN8A | |
| SCHEMBL514804 | 0.74 | IDO1 (0.50) | EPHX2PPARGPOLBIDO1SCN8A | |
| SCHEMBL28170854 | 0.74 | SCN8A (0.52) | EPHX2PPARGPOLBIDO1SCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | EPHX2 3496/4885PPARG 740/4885POLB 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.